Notably, the 2017 American College of Cardiology (ACC) Expert Decision Pathway for Optimization of Heart Failure Treatment included an “intermediate” recommendation to consider SGLT2 inhibitors in patients with HF and diabetes [81]. This evidence concerns the gene SLC5A2 and heart failure.